LONDON — Global healthcare communications consultancy 90Ten, part of Envision Pharma Group, has expanded to the US and appointed Kate Paxton as its US head.

Paxton’s experience ranges from corporate and product communications and advocacy relations to celebrity campaigns and issues management, including almost 23 years at Ketchum, where she held multiple leadership positions, including managing director of health in London and health practice director in Washington, DC.

She joins 90Ten after an 18-month stint at JPA Health, where she designed and led campaigns for several biotech companies focused on oncology and rare diseases.

Paxton told PRovoke Media: “I came to know 90Ten during my time in London I’ve been a fan for quite some time. They have had an incredible five years of growth and achievement and I’ve admired how they deliver bold, brave, creative campaigns that are clearly effective. Expanding to the US was always on the cards but Covid delayed the move by around a year before I was brought on board to steer an already-mighty ship towards new waters.”

90Ten is currently recruiting the first five members of Paxton’s team, and she says the firm’s ambition in the US is high: “There is pent-up demand with our existing client base for a US-based team to help them achieve their goals here. The referral opportunities in the US are endless, thanks to the affiliation that 90Ten has with the Envision Pharma Group and the incredible breadth of clients they already work with, from leading start-up biotechs through clinical development programme to the biggest pharma companies looking for product communications.”

And Paxton added that being part of Envision Pharma was an asset for 90Ten as it grows: “I believe there is a need in the agency world to give clients greater access to true bench strength in scientific communications. I have always felt that PR agencies were too light on the expertise when it came to real scientific grounding and understanding, and offering clients the opportunity to tap into expert medical writers, scientific designers and videographers, experts in market access and medical meetings and scientific comms, so this is the perfect marriage that the market will respond to.”

The move follows other leadership changes at the agency in the wake of its acquisition by Envision Pharma Group last year and the departure of founders Carole North and Paul Tanner. In May, 90Ten shook up its senior leadership team in the UK, promoting deputy MD of PR Claire Long and client services director Sabrina Gomersall to joint managing directors of communications.

Of Paxton’s appointment, Envision Pharma Group CEO David Thompson said: “We are thrilled to have such an experienced and passionate professional like Kate join the growing 90Ten team. Kate’s long history of building strategic and creative programs for healthcare clients of every size and scope – in addition to her deep understanding of how agencies grow and thrive – makes her ideally suited to lead us through this next, exciting phase.”

He added: “The US PR marketplace is highly competitive, but given the pairing of Envision’s footprint and deep scientific capabilities with 90TEN’s award-winning, behavioral science approach, we are confident that 90Ten US represents an exciting new offering for the American market.”

Based in London, 90Ten – named as PRovoke Media’s EMEA healthcare agency of the year in 2020 – works with half of the world’s top 20 pharma companies.